Primary Immunodeficiency

All categories, Therapeutic Indication

Leniolisib Shows Activity Across Genetically Defined Immune Dysregulation

Pharming reported positive topline data from 13 participants with genetically defined primary immunodeficiencies linked to PI3K signaling. In the open label within patient dose escalation study, leniolisib produced a mean 26.4 percent spleen volume…

admin
September 22, 2026

All categories, Therapeutic Indication

Takeda TAK-881 Wins Pivotal Phase 2/3 in PID

Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease previously treated with immunoglobulin therapy, met its primary endpoint demonstrating pharmacokinetic comparability to HyQvia. The trial evaluated TAK-881…

admin
May 6, 2026

Leniolisib Shows Activity Across Genetically Defined Immune Dysregulation

Takeda TAK-881 Wins Pivotal Phase 2/3 in PID

Saturday Rounds